Acumen, LLC
500 Airport Blvd. Suite 365
Burlingame, CA 94010
Submitted via macra-clinical-committee-support@acumenllc.com
Subject: 2024 Cost Measure Field Testing-Wave 6 Movement Disorders Cost Measure
To whom it may concern:
On behalf of the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), representing more than 4,000 neurosurgeons in the United States, we appreciate the opportunity to provide feedback on the episode-based cost measure currently being field tested titled, “Movement Disorders: Parkinson’s and Related Conditions, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS).”
Click here to read the full AANS and CNS Comment on Cost Measures for Movement Disorders.
